Vensobafusp alfa

文索芙普α

Report date: 2025/06/18 14:58:49

Base Information

Drug NameVensobafusp alfa
Drug Alias NameRecombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminusP014KP-104
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement system proteins inhibitorsanti-Complement C5
TargetsComplement system proteinsComplement C5
Therapy Area/IndicationsLupus Erythematosus, SystemicThrombotic MicroangiopathiesHemoglobinuria, Paroxysmal +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesKira Pharmaceuticals LLC
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesKira Pharmaceuticals LLCKira Pharmaceuticals (Suzhou) Ltd
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicThrombotic MicroangiopathiesHemoglobinuria, Paroxysmal +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A